Investigational drug · Phase 2
HEC88473
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 2 Diabetes.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "HEC88473"
First trial start
2023
Dec 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HEC88473", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HEC88473" as an intervention, largest first.
- Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
Dongguan HEC Biopharmaceutical R&D Co., Ltd.Industry
NCT06148649 · 234 participants · Start Dec 10, 2023 · Primary completion Feb 27, 2025
Drug: HEC88473, Placebo, Dulaglutide · For: Type 2 Diabetes
Sites: Beijing, China; Shijiazhuang, China
- A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM SubjectsPivotal-lookingCompleted
Dongguan HEC Biopharmaceutical R&D Co., Ltd.Industry
NCT05943886 · 164 participants · Start Aug 11, 2021 · Primary completion Feb 17, 2023
Drug: HEC88473 injection; Placebo · For: Healthy Subjects; Obesity; T2DM (Type 2 Diabetes Mellitus)
Sites: Changchun, China
- The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy SubjectsCompleted
Dongguan HEC Biopharmaceutical R&D Co., Ltd.Industry
NCT04829123 · 64 participants · Start May 14, 2021 · Primary completion Mar 2, 2022
Drug: HEC88473 injection; Placebo · For: Non-alcoholic Steatohepatitis
Sites: Sydney, Australia
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07616037 · 30 participants (planned) · Start Jun 2026 · Primary completion Jun 2027
Drug: GLP-1/FGF21 dual agonist (HEC88473) · For: PCOS (Polycystic Ovary Syndrome)
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
Xiang L, Wang G, Zhuang Y, et al. · J Hepatol 2025
- First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.
Zhang H, Li Q, Chen H, et al. · BioDrugs 2025
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.